A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
NCT ID: NCT01376323 Phase: PHASE2 Status: COMPLETED Enrollment: 92 Completion: 2012-09-17
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK256073 1mg, GSK256073 5mg, GSK256073 10mg, GSK256073 25mg, Placebo, Sitagliptin 100mg
Summary
The aim of this combined, two part study is to evaluate the safety and glucose lowering effects of GSK256073 when administered to diabetic subjects for 12 weeks.
Primary Outcome
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)